Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MERU
- Sponsors AbbVie; AbbVie Germany
- 07 Jun 2022 Results of baseline genomic data in the MERU cohort to interrogate SCLC's heterogeneous TME and tumor-intrinsic molecular and genetic drivers for therapeutic vulnerabilities, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 03 Apr 2021 Primary endpoint (Overall survival (OS)) has not been met according to results published in the Journal of Thoracic Oncology.
- 03 Apr 2021 Results published in the Journal of Thoracic Oncology